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Abstract
Objective: To evaluate seed stability after permanent implantation in the parotid gland and periparotid region via a
three-dimensional reconstruction of CT data.
Material and methods: Fifteen patients treated from June 2008 to June 2012 at Peking University School and
Hospital of Stomatology for parotid gland tumors with postoperative adjunctive 125I interstitial brachytherapy
were retrospectively reviewed in this study. Serial CT data were obtained during follow-up. Mimics and Geomagic
Studio software were used for seed reconstruction and stability analysis, respectively.
Results: Seed loss and/or migration outside of the treated area were absent in all patients during follow-up
(23–71 months). Total seed cluster volume was maximized on day 1 post-implantation due to edema and decreased
significantly by an average of 13.5 % (SD = 9.80 %; 95 % CI, 6.82–17.68 %) during the first two months and an average
of 4.5 % (SD = 3.60 %; 95 % CI, 2.29–6.29 %) during the next four months. Volume stabilized over the subsequent
six months.
Conclusions: 125I seed number and location were stable with a general volumetric shrinkage tendency in the
parotid gland and periparotid region. Three-dimensional seed reconstruction of CT images is feasible for
visualization and verification of implanted seeds in parotid brachytherapy.
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Introduction
Over the past decade, local surgical resection combined
with 125I seed implantation brachytherapy has been ac-
cepted as a potential alternative curative treatment for
malignant salivary gland tumors. Its advantages include
functionally preserving the facial nerve and improving
the local control rate [1–7].
In parotid brachytherapy, a high degree of seed stability
should theoretically ensure a constant, uniform dose deliv-
ery to the target volume. If seeds are repositioned due to
migration, the alteration leads to adverse dosimetric con-
sequences, resulting in either “hot spots,” which cause
severe complications, or “cold spots,” which reduce ad-
equate therapeutic dose coverage, thus increasing the risk
of recurrence. Moreover, poor seed stability increases the
possibility of individual seeds migrating out of the target
volume and also results in untoward effects to the organ
of migration [8–10].
Previous reports described factors involved in seed
dislocation and migration in prostate brachytherapy
[10–13]. However, these reports were based on two-
dimensional X-ray imaging, which had the drawback of
insufficiently visualizing the seeds due to overlap and
seed-induced artifacts in the radiographs. To date, the
stability and safety of 125I seeds in head and neck im-
plant have not yet been described. Furthermore, the
complexity of maxillofacial anatomical structures
makes seed verification even more difficult.
In this study, a three-dimensional (3D) visualization
and verification method for implanted 125I seeds is
established. Additionally, a detailed periodic observation
of seed stability in the parotid gland and periparotid
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region is reported to evaluate the therapeutic effect and
safety of parotid brachytherapy.
Materials and methods
Patient characteristics
Fifteen patients (6 males and 9 females) aged from 22
years to 62 years (median 45.8 years), who were treated
from June 2008 to June 2012 at our institution for pri-
mary parotid gland tumor with post-operation adjunct-
ive 125I interstitial brachytherapy, were retrospectively
analyzed in this study (Table 1). The median follow-up
duration was 36 months (range 23–71 months), during
which time none of the 15 patients showed evidence of
local recurrence. The study was approved by the Ethics
Committee of Peking University School and Hospital of
Stomatology, and written informed consent was ob-
tained from each patient. The criteria for eligibility were
as follows:
1. Adults patients who underwent permanent 125I seed
interstitial brachytherapy after primary parotid gland
tumor resection with facial nerve preservation [5];
2. Histologically proven parotid gland tumor with
focally close margins or micro-residual disease due
to tumor characteristics;
3. Available CT scans from at least four fixed time
points: post-implantation day 1, 2 months, 6 months
and 12 months, performed under uniform standards
to ensure a voxel-based spatial normalization for
comparison: CT scanner (Siemens AG, Munich,
Germany) at 120 kV and 150 mA with a slice
thickness of 0.75 mm;
4. No history of secondary surgery in previously
treated maxillofacial area or medical record of
external beam radiation therapy.
125I radioactive seed implantation
Radioactive seed implantation was performed postopera-
tively in all patients. The planned target volume was out-
lined by oncologists to cover the lesion with a 0.5–1.0 cm
margin, using a computerized treatment planning system
(BTPS, Beijing Atom and High Technique Industries,
Beijing, China) (Fig. 1a). The diameter and length of each
seed (Model 6711, Beijing Atom and High Technique
Industries Inc., Beijing, China) were 0.8 mm and 4.5
mm, respectively, with a half-life of 59.6 days. Seed ac-
tivity ranged from 0.6 to 0.8 mCi. The planned dose
(PD) ranged from 100 to 120 Gy. Seeds were implanted
using needles with 1.0 cm spacing, center-to-center,
throughout the target volume, in accordance with the
implantation plan (Fig. 1b). The target volume included
the residual parotid gland, adjacent muscles of mastica-
tion and, in some cases, sub-cutaneous tissue. Doses
delivered to organs at risk were designed within accept-
able limits of tolerance. One day following 125I seed im-
plantation in the tissues, a post-implant CT scan was
obtained for verification and qualification of the treat-
ment (Fig. 1c) comparing the D90, V100,and V150 indi-
ces with those in the preplan (Fig. 1d). All patients
were re-scanned approximately every two months for
the first six months and were evaluated every six
months or sooner if a new clinical sign or symptom ap-
peared. Seed stability analyses were conducted using
longitudinal and cross-sectional comparisons.
Table 1 Patient demographics and clinical characteristics of 125I seed implantation
Patient no. Gender Implant side Age (ys) Number of seeds PD (Gy) Seed activity (mCi) Postoperative pathology
1 M R 41 41 100 0.8 Mucoepidermoid carcinoma
2 M R 52 30 120 0.8 Oncocytic carcinoma
3 M L 46 51 100 0.8 Myoepithelial carcinoma
4 F L 35 37 110 0.8 Mucoepidermoid carcinoma
5 F L 60 32 120 0.8 Mucoepidermoid carcinoma
6 F L 56 49 110 0.8 Mucoepidermoid carcinoma
7 F L 43 58 120 0.7 Adenoid cystic carcinoma
8 F L 55 55 120 0.7 Adenocarcinoma
9 F R 22 52 120 0.7 Adenoid cystic carcinoma
10 M L 46 49 100 0.7 Carcinoma in pleomorphic adenoma
11 F R 46 37 110 0.6 Mucoepidermoid carcinoma
12 M L 38 40 110 0.6 Carcinoma in pleomorphic adenoma
13 F R 62 41 110 0.7 Adenocarcinoma
14 M R 58 45 120 0.7 Adenoid cystic carcinoma
15 F L 27 18 120 0.6 Acinic cell carcinoma
Abbreviations: M male, F female, L left side, R right side, PD planned dose
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Seed visualization and verification
To visualize and verify the presence and positioning of
the seeds, Dicom format pictures (0.75 mm slice) from
the original CT scan under uniform voxel-based nor-
malization were imported into Mimics software (ver-
sion 15.0, Materialise NV, Leuven, Belgium). Major
segmentation technology was utilized on the threshold
of different CT values and the 3D models were recon-
structed for both bony structures and the seeds. These
models were able to be rotated, allowing visualizing
the localization of each seed. Models were stored in
STL format and introduced into Geomagic Studio
software (version 12.0, Geomagic Inc., Morrisville,
NC, USA) for further analysis.
In this software, our registration process typically in-
volves two main phases. First, a rigid transformation of
bone (considered as the fixed anatomical structure) was
conducted with ‘best fit registration function’. Second,
the coordinates of their counterpart seeds were aligned
into the uniform coordinate system by finding their bony
correspondences. Therefore, seeds were also rigidly
transformed into the same coordinate frame for a longitu-
dinal comparison.
Seed stability index: changes in number and location of
seeds
The number of seeds was calculated in the reconstructed
3D models and then compared with intraoperative med-
ical records. Longitudinal comparison was conducted
qualitatively using a color-coded spectrum to reflect the
magnitude of seed displacement, and their location were
defined as follows:
Minimum bounding box
The minimum bounding box was defined as the smallest
bounding or enclosing box used in geometry. In this study,
for a point set in three dimensions, this measure referred to
the box with the smallest volume within which all of the re-
constructed 125I seeds were contained. The algorithm used
in the Geomagic software detected the minimum seed clus-
ter boundaries automatically and presented this as a rect-
angular box, as seen in Fig. 2. Expansion and shrinkage
Fig. 1 The administration of 125I seed parotid brachytherapy. a Isodose curve in the implant plan from CT scan. b Needle implantation
c Isodose curve after seed implantation from CT scan. d Dose volume histograms of PTV after seed implantation
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magnitudes of seed clusters were calculated based on
changes in the box’s volume. The percent volume change
was measured as (Vtime1-Vtime2)/Vtime1*100 %.
Seed cluster geometric center (x , y , z)
The centroid of each seed was automatically determined
by Geomagic software. The geometric center for a seed
cluster was determined as the mean of the coordinates
of each axis.
The x coordinate of the geometric center x, was com-
puted as
x ¼ x1 þ x2 þ x3…þ xn
n
; n
¼ number of seeds implanted in the patient:
The y and z coordinates of the geometric center were
computed in the same manner.
Inter-seed distance (d)
Volume changes of the seed clusters were measured ac-
cording to the minimum bounding box, as described
above; however, the minimum bounding box only con-
siders the seed cluster as a whole and only interprets
the outer contour, regardless of each seed location.
Thus, changes within seed clusters were further eval-
uated according to the distance between each seed and
the geometric center ( x , y , z ) of its seed cluster,
assessed as the change in distance over the course of
periodic observation.




xn−xð Þ2 þ yn−yð Þ2 þ zn−zð Þ2
q
Mathematically, the change in distance, d, represents
the relative change in the seed cluster dimensions. Spe-
cifically, an increase in mean d signals volumetric expan-
sion or an acentric tendency of the seeds, and a decrease
represents their volumetric shrinkage or a central
tendency.
Correlation of clinical factors and seed stability index
Clinically relevant parameters such as age, gender, im-
planted side of the parotid gland, planned dose and
number of seeds and activity of the seeds were corre-
lated with changes in dimensions.
Statistical analysis
Descriptive statistics of the tumor characteristics and
treatment features were calculated for each patient. To
evaluate the magnitude of seed cluster expansion or
shrinkage, the aforementioned measurements were ob-
tained and then compared by repeated measures ana-
lysis of variance (ANOVA) using the SPSS statistical
package (SPSS 13 Inc., Chicago, IL, USA). Correlation
analysis for clinical relevance was also performed, and
statistical significance was evaluated using two-tailed
tests with P < 0.05.
Fig. 2 Schematic diagram of 3D seed reconstruction
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Results
Seed stability index
Change in number of seeds
The number of seeds was calculated based on a 3D re-
construction of each scan and then compared with the
number of seeds listed in the intraoperative medical re-
cords for each patient. In all 15 patients, the expected
number of seeds was visualized within the treated area,
with none lost or migrated from the area.
Change in volume over time
Periodic observation provided a way to qualitatively assess
the minimum bounding box volume for each patient, as
shown in Table 2 and Fig. 3. Overall, each patient exhib-
ited a similar trend of decreased volume over time
(Fig. 3a). On post-implantation day 1, seed cluster volume
was at its maximum (Fig. 3b). A significant (P = 0.007)
total volume decrease averaging 13.5 % (SD = 9.80 %; 95
% CI, 6.82–17.68 %) was observed during the first two
dose delivery months (first half-life of the isotope), and a
significant (P = 0.017) decrease averaging 4.5 % (SD = 3.60
%; 95 % CI, 2.29–6.29 %) was observed during the next
four months. Over the subsequent six months, total vol-
ume slowly approached a constant value (P = 0.295).
The inter-seed distance further illustrated the expand-
ing or acentric tendency of the seeds within the mini-
mum bounding box. As shown in Fig. 3c (each patient)
and Fig. 3d (general trend), inter-seed distance decreased
gradually during the first six months after implantation,
and the greatest degree of central tendency came during
the first half-life of the dose delivery period (P = 0.008).
Longitudinal comparison with color-code spectrum
In eight patients with longer observation periods,
spectrum analysis qualitatively indicated that implanted
seeds were relatively stable, especially those in the per-
iphery, and seeds in the center area continued to shrink
within the tissue. This trend is illustrated in patient No.3
as an example during a 4-year follow-up (Fig. 4).
Correlation of clinical factors and seed stability index
Correlation analysis (Table 3) indicated that the num-
ber of implanted seeds was the only clinical factor asso-
ciated with change in volume (P = 0.014) (Table 2);
however, it was not associated with change in inter-
seed distance (P = 0.214) (Table 3). Notably, the
planned doses were not discrepant.
Discussion
Permanent 125I seed implantation has been used over
the past decade in the management of parotid gland ma-
lignant tumors with an 88.7–100 % 5-year local control
rate and benefit of preserving the facial nerve [3, 5, 14].
Glaser et al. [4] reported disease-free survival for cases
of head and neck cancer (8 of 18 patients had ACC) of
53 % at 5 years following surgery and 125I implantation
without any additional complications. Zhang et al. [5] re-
ported a 100 % LC rate and no complications (follow-up
of 50–74 months, median 66 months) in patients with
residual parotid malignant tumors post-surgery treated
solely with 125I brachytherapy. Zheng et al. [15] re-
ported that children and adolescents with parotid gland
cancer treated with 125I seed implantation brachyther-
apy demonstrated satisfactory short-term effects with
few complications.
As the radioactivity of the seeds decays over time, the
seeds need to remain permanently within the treatment
area. But gradually, changes in seed spacing do occur,
for the seed cluster itself will expand or contract with
the tissue into which the seeds are embedded due to
speech, mastication, daily facial care or radiation conse-
quences [16, 17]. Mathematically, the seeds used in
interstitial brachytherapy are small enough to dislocate
and migrate through the vascular system and lodge in
distant tissue. The percentage of patients who have a
least one seed migrate to the chest after prostate brachy-
therapy varies widely from 0.7 % to 55 % [10–12]. And
in extremely low risk, this seed migration may cause
pneumonitis and carcinogenesis [18, 19] However, no re-
port in the literature has addressed the stability and
safety of these seeds in the parotid gland and periparotid
region.
As shown in this study of 15 patients, the number of
seeds within the treated area remained stable during the
follow-up period. The Seed Stability Index demonstrated
that maximum seed cluster volumes were observed on
post-implantation day 1 and then decreased dramatically
by a mean of 13.5 % during the first two dose delivery
months (the first half-life of the isotope), during which
time the parotid swells due to treatment-induced trau-
matic edema and the radionucleotides decay at their
fastest rate. This volume change resulting from post-
implant edema has also been documented in prostate
brachytherapy, and swelling typically decreases and
eventually returns to the pre-implant volume [19–21].
Radiation-induced tissue shrinkage can be clearly in-
ferred by an average of 4.5 % decrease in seed cluster
volume from post-implantation month 2 to month 6.
The volume reached a relatively constant level after six
months. Because the half-life of isotope 125I is only 59.6
days, approximately 90 % of the radiation dose is deliv-
ered within 180 days for 125I radionuclides, after which
the remaining dose can generally be ignored.
Inter-seed distance analysis revealed similar volumet-
ric shrinkage during the first 6 months after implant-
ation. Spectrum analysis qualitatively confirmed this
pattern and showed that the shrinkage was more obvi-
ous among the central seeds than the peripheral seeds.
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The divergence is understandable because radiation-
induced tissue shrinkage would be expected to bring seeds
closer together in the area where tissue is receiving rela-
tive a higher dose. According to the dose distribution pat-
tern, tissues near peripheral seeds received relative lower
dose [20, 21]. Thus, shrinkage is less pronounced.
Histologically, parotid gland tissue is vulnerable to
radiation-induced damage [22], principally following an
early inflammatory phase followed by a late glandular at-
rophy with fat replacement and possible tissue fibrosis
[23, 24]. During brachytherapy, each 125I seed sends out
Fig. 3 Seed Stability Index. All stability studies were based on CT data from four fixed points in time: 1 = day 1 post-implantation; 2 = 2 months
post-implantation; 3 = 6 months post-implantation; and 4 = 12 months post-implantation. a Minimum bounding box volume per patient over
time; b average minimum bounding box volume over time; c average inter-seed distance (d) per patient over time; d average inter-seed distance
(d) over time. *Error Bars: +/− 2 standard error (SE)






1a 119.17±46.44 - 19.20±3.00 -
2 103.09±38.73 0.007* 17.96±2.82 0.008*
3 98.51±36.27 0.017* 17.47±2.96 0.183
4 95.34±35.85 0.295 17.27±3.02 1.000
Time 1 = day 1 post-implantation; 2 = 2 months post-implantation; 3 = 6
months post-implantation; and 4 = 12 months post-implantation. aChanges for
time points 2 – 4 were assessed against their former time point
*Statistically significant (P≤0.05)
Table 3 Correlation of clinical factors with seed stability index
changes from post-implantation day 1 to month 12





Gender -0.185 0.508 -0.18 0.52
Age 0.36 0.163 -0.097 0.794
Implant side 1.141 0.617 -0.398 0.142
Planned dose -0.072 0.798 -0.201 0.452
Seed number 0.621 0.014* 0.341 0.214
Seed activity -0.017 0.953 0.14 0.62
*Statistically significant (P≤0.05)
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a localized, continuous low dose of X-rays and γ-rays,
thereby enabling a higher cumulative dose up to 160Gy
[25, 26], high enough to induce fibrosis, which is con-
sidered a common and irreversible effect of radiation.
This effect creates a “seed holder” to help maintain seed
position at the implantation site. More specifically, the
non-uniform dose distribution leads to inhomogeneous
radiation absorption from central to peripheral tissues.
Therefore, the cumulative effect of multiple small doses of
radiation in the central area might be even more dramatic,
continually causing irreparable damage over time.
No significant correlation was noted between changes in
either the minimum bounding box or inter-seed distance
seed cluster volume and patient characteristics such as
age, gender or implant side of the parotid gland. The only
significant factor predicting these cluster volume changes
was the number of implanted seeds (P = 0.014 and
P = 0.214, respectively). Since no large discrepancies
were seen for planned dose and seed activity in the
patients, this relations need to be verified in more cases.
This study presents the first periodic observation and
qualitative assessment of interstitial brachytherapy seed
stability in terms of number and location of seeds in the
parotid gland and periparotid region. We also present a
new method for seed reconstruction from segmented
CT images, and the ability to reconstruct the implanted
seeds post-operatively allowed us to evaluate seed migra-
tion from the implant site. Traditionally, planar X-ray
images are insufficient to accurately visualize brachyther-
apy seeds [27–29], while radiographs taken by a radio-
therapy simulator renders part of the matching problem
but are still complex. Using our reconstruction models,
the 3D coordinates of the implanted seeds can be calcu-
lated and viewed in 3D space, resolving the problem of
overlapping seeds that comes with conventional X-ray
radiography. Although some reconstruction algorithm
errors and distortions occurred due to the condition and
quality of the primary CT images, this method is suffi-
cient for visualization and verification of 125I seeds in
parotid brachytherapy.
Limitations to this technique should be noted. As the
timing of a patient’s CT scans sometimes varied from
the routine follow-up schedule, we encountered missing
data for longer cross-sectional comparisons. Further-
more, this method of 3D seed reconstruction is still
largely dependent on the quality of CT data and the abil-
ity to deal with an arbitrary number of seeds and various
implanted areas without any loss in speed or accuracy,
all of which requires further testing.
Promisingly, although this procedure is still mainly in-
vestigational, it is likely to be an alternative method for
predicting recurrence status from exaggerated or obvi-
ous dislocations of seeds, thus serving as a conservative
examination to avoid invasive dissection in the future.
Conclusion
In conclusion, our periodic observation provides a quali-
tative assessment for permanently implanted seed stabil-
ity in the parotid gland and periparotid region. Our
preliminary short-term results demonstrate consistent
seed number counts and robust localization, which en-
sure safety and a curative effect. The 3D reconstruction
method is feasible for visualization and verification of
seeds in the head and neck region and overcomes the
Fig. 4 Color-coded spectrum analysis for patient No.3 over time. Seed clusters tended to shrink with time, and seeds in the central area changed
more dramatically during long-term follow-up. Seeds in the periphery were relatively stable
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problems of overlapping and seed-induced artifacts
present with conventional radiographs. A larger number
of patients and longer follow-ups are warranted to pro-
vide further data concerning this issue and the efficacy
of this method.
Abbreviation
125I: Iodine-125; TPS: Treatment planning system; PD: Planned dose;
3D: Three dimensional.
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